Background-Limus-eluting stents are dominating coronary interventions, although paclitaxel is the only drug on balloon catheters with proven inhibition of restenosis. Neointimal inhibition by limus-coated balloons has been shown in few animal studies, but data from randomized clinical trials are not available. The aim of the present preclinical studies was to achieve high and persistent sirolimus levels in the vessel wall after administration by a coated balloon. Methods and Results-Different coating formulations and doses were studied in the porcine coronary model to investigate sirolimus tissue levels at different time points as well as efficacy at 1 month using quantitative coronary angiography and histomorphometry. Loss of the selected coating in the valve, guiding catheter, and blood was low (2±14% of dose). Acute drug transfer to the vessel wall was 14.4±4.6% with the crystalline coating, whereas the amorphous coatings were less effective in this respect. Persistence of sirolimus in the vessel wall until 1 month was 40% to 50% of the transferred drug. At 1-month follow-up, a modest but significant reduction of neointimal growth was demonstrated in a dose range from 4 μg/mm 2 to 2×7 μg/mm 2 , for example, maximum neointimal thickness of 0.38±0.13 versus 0.65±0.21 mm in the uncoated control group. Conclusions-Various sirolimus-coated balloons effectively reduce neointimal proliferation in the porcine coronary model but differ considerably in retention time in the vessel wall. It has to be determined if such a formulation with persistent high vessel concentration will result in a relevant clinical effect. (Circ Cardiovasc Interv. 2016;9:e003543.
P aclitaxel-coated balloon (PCB) catheters have evolved into a first-line treatment option for superficial femoral artery disease [1] [2] [3] [4] and coronary in-stent restenosis 5-10 with a class I level A recommendation in the European Guidelines for Revascularization. 11 Furthermore, the use of PCB as standalone therapy represents the most rigorous approach to establish the concept of leaving nothing behind. 12, 13 However, in coronary artery disease, the combination of PCB and baremetal stents turned out to be inferior to current generation limus-eluting stents. [14] [15] [16] Furthermore, conflicting data have been reported for PCB in the treatment of below the knee disease. 4, [17] [18] [19] Persistence of paclitaxel in the vessel wall after a single local administration with a coated balloon has been proposed as one mechanism of action for PCB. 20 Irreversible binding to microtubules 21 and the detection of paclitaxel in solid tumors 1 week after a single intravenous administration in patients 22 give some indication of the peculiarity of its pharmacokinetics. Although paclitaxel is the only drug on clinically proven and US Food and Drug Administration approved balloon catheters, coronary interventions are dominated by limuseluting stents. 23 Few studies indicate neointimal inhibition by limus-coated balloons in animals 24 especially for zotarolimus, 25, 26 but no data from randomized clinical trials have been published. For stent-based local drug delivery, it has been shown that sirolimus must be released for a period of several weeks for effective inhibition of neointimal proliferation. 27 Sirolimus reversibly binds to FKBP 12 and potently inhibits cell proliferation by forming a complex with the mammalian target of rapamycin, thus blocking cell cycle progression at the juncture of the G1 and S phases. 28 The goal of the current preclinical research project was to identify a formulation of sirolimus on angioplasty balloon catheters providing high transfer of the drug to the vessel wall, long persistence, and measurable inhibition of neointimal proliferation. Different excipients were investigated to achieve a high enough sirolimus tissue level for an extended period of time.
In Vivo Experiments
All animal experiments and housing were conducted in accordance with the guidelines for animal experiments set forth by the animal protection committee of the Sachsen Anhalt government, Germany. Anesthesia of the animals and the interventional procedure, except for the sequence of balloon dilatation and stenting, were previously described. 29 Briefly, the coronary arteries of castrated male swine (≈3 months old) were imaged using standard angiographic techniques via the left carotid artery. Before start of each experiment, a randomization list was created. All animals were orally treated with acetylsalicylic acid and clopidogrel starting 2 days before the intervention and continuing until euthanization. Target segments were selected in the left circumflex, left anterior descending (LAD), and in some studies right coronary arteries.
For the pharmacokinetic studies, coated balloons with or without stents were each inflated in all 3 coronary arteries applying moderate overstretch for 60 s, then deflated and retracted. In the case of balloons without stent, marker stents were first implanted followed by deployment of the balloons immediately proximal or distal to the marker stents. Approximately 10 minutes after the last balloon inflation, at 1 week, or after 1 month the animals were euthanized. After rapid explantation of the hearts, the entire treated coronary artery segments, including ≈5-mm distal and proximal to the balloon edges, were dissected. Surrounding tissue was eliminated, finally leaving the artery including neotinima, media, and adventitia. Therefore, all layers of the artery but not surrounding tissue were included. The treated coronary arteries were kept frozen for drug content analysis.
For the efficacy and tolerance studies (1-month follow up), pigs were randomized to the respective treatment groups (Table 1) . Animals were selected without knowledge of the randomization groups. Furthermore, individuals taking care of the animals, quantitative coronary angiography, and histology were fully blinded for the treatment groups. Bare-metal stents mounted on coated or uncoated balloons were implanted with an oversize ratio of about 1.2. Followup angiography was performed after 1 month. The treated vessel segments were dissected for quantitative histomorphometric analysis and histopathologic evaluation of the treatment site. Samples from myocardium downstream were selected for histology.
Quantification of Sirolimus

Sirolimus on Unused and Used Coated Balloons
The loss of sirolimus during passage through a blood-filled hemostatic valve (off/closed mechanism) and 6 French guiding catheter and 1 minute in stirred blood kept at 37°C was investigated in vitro. For determination of sirolimus content, unused and used balloons were placed in a vial, inflated, and cut off from the catheter shaft. A defined
WHAT IS KNOWN
• Limus-eluting stents are dominating coronary interventions, although paclitaxel is the only drug on balloon catheters that has been shown to reduce restenosis.
• For stent-based local drug delivery, that sirolimus must be released for a period of several weeks for effective inhibition of neointimal proliferation.
WHAT THE STUDY ADDS
• Various sirolimus-coated balloons effectively reduce neointimal proliferation in the porcine coronary model but differ considerably in retention time in the vessel wall.
• It has to be determined if a formulation with persistent high-vessel concentration will result in a relevant clinical effect. volume of ethanol (>96%) was added. The vials were closed, shaken, treated with ultrasound for 30 min and centrifuged. The loss is the difference in drug content between unused balloons and balloons after exposure to blood.
Measurement of Sirolimus on Balloons and in Vessel Wall
For extraction of sirolimus, a defined volume of ethanol was added to tissue samples to achieve an ethanol concentration of >70%. The samples were homogenized (Precellys 24 Dual Homogenizer, PEQLAB Biotechnologie GmbH, Erlangen, Germany), treated for 30 minutes with ultrasound at room temperature, and then centrifuged for 10 minutes.
Sirolimus was determined by high-performance liquid chromatography using ultraviolet detection; column: C18, 5 μm, 250×4.6 mm, mobile phase: 70% acetonitril and 30% distilled water with 0.005% trifluoroacetic acid, 1 mL/min, column temperature 40°C, detection: 278 nm, retention time: about 18 minutes. A standard solution was injected during the same run. Tissue samples with low sirolimus content were measured by combined liquid chromatography/mass spectrometry. Column: C18, 3.5 μm, 100×2.1 mm, mobile phase: 83% methanol and 17% 25-mmol/L ammonium acetate buffer with 8.5-μL acetic acid per 100 mL buffer, 0.2 mL/min, column temperature: 40°C; detection: 931.5/864.5 AMU, retention time: about 10 minutes. At least 20 μL of the sample was injected into the highperformance liquid chromatography unit. A calibration curve was generated during the same run.
Sirolimus tissue levels are reported as total amount of drug in the vessel wall and the percentage of drug in the wall compared with the total amount of drug on the balloon. Percentage of drug in the vessel wall became an established measure for the efficacy of drug-coated balloons. 23, 25, 29, 30 
Sirolimus in Blood
Different from many other drugs, sirolimus concentration is high in erythrocytes and low in plasma. Therefore, measurement in blood was selected. Ten minutes after treatment with coated balloons, blood samples were collected from the guiding catheter and sirolimus was measured. The early time point was selected because blood level is expected to be highest soon after intravascular administration. Two milliliter of blood were extracted with 2-mL methyl tert-butyl ether/n-butyl chloride (1:1); extracts were evaporated, the dry material dissolved in methanol and analyzed by high-performance liquid chromatography/mass spectrometry (same method as for tissue with low sirolimus content).
Quantitative Angiographic Analysis
Coronary artery and left ventricular imaging was performed using an AXIOM Artis zee fluoroscope (Siemens, Erlangen, Germany). The CAAS II System (Pie Medical, The Netherlands) was used for quantitative coronary analysis by experienced observers blinded to the treatment groups. Left ventricular ejection fraction was quantified using the Siemens module (Axiom Artis dBC, Siemens, Germany).
Histopathology
Treated Vessel Segment
The target segments were embedded in methyl-methacrylate (Heraeus Kulzer, Wehrheim, Germany). Two in-stent sections and segments proximal and distal to the stent were stained by hematoxylin and eosin, and 1 in-stent section was stained by Masson Goldner. Histomorphometric measurements were taken using the NIS BR 3.0 image program. Luminal diameter, external elastic lamina diameter (=vessel diameter), maximal neointimal thickness, external elastic lamina area (=vessel area), luminal area, and neointimal area were evaluated. Scores of injury and inflammation were assigned as described by Schwartz et al 31 and by Kornowski et al, 32 respectively.
Myocardium
The hearts were examined for pathological anomalies. Tissue samples were taken from the left ventricle close to the septum (representative for the LAD), the right ventricle close to the right coronary artery, and lateral to the apex (circumflex), and examined for histological evidence of hemorrhage, thrombosis, fibrosis, necrosis, scar formation, as well as evidence of endocarditis and epicarditis.
Table 2. Selection of Preferred Coating: Sirolimus Content of 3.5 × 20 mm on Sirolimus-Coated Balloon Catheters Before and After Use in Porcine Coronary Arteries, Drug Content of Treated Vessel Segments 10 Minutes Post Balloon Inflation and 1 Month Later
Statistical Analysis
Histomorphometric variables of the 3 cross-sectional planes within the stent were averaged to obtain a mean value per treated segment. 
Results
Evaluation of Basic Properties of Different Coating Approaches
To evaluate acute and 1-month sirolimus tissue levels, coated balloon catheters without or with premounted stents with the amorphous sirolimus coating (AS coating, 1 μg/mm 2 ), less 4±4.6% of dose on the balloon, no premounted stent), 8.6±2.0% of dose with the AS 1 (low dose) coating but <1% with the high-dose AS 7. With the IIIb coating, 5.1±3.4% of dose was transferred to the vessel wall. A striking difference was observed with respect to persistence of the drug in the vessel wall at the end of the 1-month observation period. Whereas with formulation Vb 4 ≈50% of the initial sirolimus amount in the vessel wall was still retrieved after 1 month, <5% was left in the tissue after administration of formulations AS 1, AS 7, and IIIb ( Table 2 ). This means in case of formulation Vb 4, a half-life of the drug in the vessel wall of 4 weeks compared with <1 week for the AS and IIIb formulations.
Adherence of sirolimus during passage through a valve, the blood-filled guiding catheter and floating in blood was only tested for the Vb 4 formulation (Figure 1 ). Mean loss was 2±14% of dose. Release during angioplasty in coronary arteries was ≥90% of dose for all formulations except for the low-dose AS coating ( Table 2 ).
Efficacy of Various Sirolimus Balloon Coatings
Twenty-four animals were treated with premounted stents on uncoated balloons, AS (7 μg/mm 2 ), Vb 4 (4 μg/mm 2 ), Vb 7 (7 μg/mm 2 ), or the paclitaxel-coated SeQuent Please balloons (3-μg paclitaxel/mm 2 , PCB). Quantitative coronary angiography revealed similar baseline parameters. Angiographic parameters indicated antirestenotic activity in all drug-treated vessel segments (Table 3 ). The PCB inhibited vessel narrowing most strongly. Inhibition by Vb 4 and Vb 7 reached the level of statistical significance versus the uncoated control in at least one of the selected criteria (Table 3) ; however, no statistical difference was found between various sirolimus compositions. Histomorphometrical analysis confirmed the angiography findings (Table 3 ; Figure 2 ).
Histology of myocardial tissue revealed mixed findings such as edema, vasculitis, myocarditis, scar, diffuse and focal inflammation, and focal degeneration. No thrombotic occlusions, necrosis, and endocarditis or epicarditis were found. Most of these findings were slight, mild, and a few were moderate. No severe histopathologic changes were found. These changes were seen for all treatments including those with uncoated balloons. No vessel occlusion because of foreign material was found.
Safety Trial
To assess the margin of safety 2 high-dose sirolimus balloons (version of Vb coating with >7 μg/mm 2 ) were inflated in the same vessel segment with complete overlap in 2 coronary arteries per pig, and compared with the same procedure with uncoated balloons. The drug content of the coated balloons was 7.8±0.5-μg sirolimus per mm 2 balloon surface for balloons with premounted stents and 7.5±0.4 μg/ mm 2 for balloons without premounted stents. The drug was almost completely released from the coated balloons during treatment with only 2.5±0.6% of dose left on balloons with premounted stent and 5.8±0.3% on balloons without stent. Treatments were well tolerated, after deflation of the catheters no ECG disturbances were recorded. During follow up, the animals of the high-dose group gained 7.9±1.2-kg body weight compared with 7.2±2.0 kg in the uncoated control, confirming that both the interventions and coatings were equally well tolerated.
Ten minutes after treatment with coated balloons, sirolimus blood concentration was 3.79±0.87 ng/mL, which is below the sirolimus target level in renal transplantation of 5 to 10 ng/mL after daily dose of 4 mg. 33 In view of the significant local overdose of sirolimus in this experiment and the lower body weight of the young pigs, the findings indicate a sufficient margin of safety.
Quantitative coronary angiography and histomorphometry revealed similar angiographic baseline parameters in both groups. Minimal lumen diameter, late lumen loss, and diameter stenosis 1 month after intervention were in favor of the high dose sirolimus coatings compared with uncoated balloons, but without statistical significance. Neointimal area was significantly lower in the group treated with sirolimus-coated balloons. A tendency toward higher inflammation and injury scores was observed in the sirolimus group (Table 4 ; Figure 3 ).
To assess possible downstream effects on myocardial function, left ventricular angiography was performed at baseline (previous to coronary intervention) and at 1-month follow up. Left ventricular ejection fraction did not differ significantly between groups, neither at baseline nor at follow up. After 1 month, left ventricular ejection fraction was slightly lower in Thrombotic occlusion of the LCX in animal A52/33 occurring during the initial procedure. The vessel was excluded from QCA and histomorphometry. At the time of treatment: vessel reference diameter (RFD initial), minimal lumen diameter instent after implantation (MLD post), and vessel overstretch after stent implantation (overstretch). At 1 month angiography: minimal lumen diameter in-stent (MLD FU stent), late lumen loss in-stent (LLL in-stent), and diameter stenosis in-stent (diasten in-stent), negative values mean persistent overstretch. Histomorphometry: vessel diameter, lumen diameter, maximum neointimal thickness, vessel area, luminal area, neointimal area, injury score, inflammation score, diameter stenosis, and area stenosis. Values are medians with interquartile range; P value is based on the F test in a mixed model with repeated measures based on ranks. Table 5 ).
Histology of dependent myocardium revealed abnormal findings in animals treated with uncoated balloons and with 2 high-dose balloons. Findings in the uncoated balloon catheter group at 1 month were mild or absent with the exception of 1 animal showing LAD occlusion. In the group treated with 2 high-dose sirolimus-coated balloons, histologically abnormal findings (vasculitis, myocarditis, and scars) graded as mild to severe were seen in the left ventricle of 4 of 5 animals. However, 3 of the 4 findings were not related to a blood vessel. Vasculitis possibly related to treatment was detected in the majority of animals and was limited to small arterial vessels. It was associated with vessel wall thickening because of hyaline swelling or exudation of fibrin with part of the animals showing concomitant edema (Table 6 ; Figure 4 ).
Comparison With a Sirolimus-Eluting Stent
Another porcine study compared a clinically well-established current generation sirolimus-eluting stent 34, 35 with bare-metal stents implanted with Vb 4 sirolimus-coated balloons. Twenty-one study devices were implanted in LAD, circumflex, and right coronary porcine arteries. Quantitative coronary angiography and histomorphometry confirmed similar baseline parameters of all groups and indicated a significant reduction of neointimal proliferation by the sirolimus-eluting stent and the Vb 4 sirolimus-coated balloon compared with uncoated bare-metal stents. However, the difference between the 2 sirolimus groups was statistically not significant (Table  7 ; Figure 5 ).
Discussion
The findings of the present preclinical studies demonstrate the feasibility of sirolimus balloon coating in a dose range of 1 to 7 μg per mm 2 balloon surface with varying amorphous and crystalline characteristics. Acute drug transfer was highest with the crystalline variants. Furthermore, the crystalline coatings resulted in the desired persistence of sirolimus in the vessel wall. At 1 month follow up, a significant and reproducible reduction of neointimal growth was demonstrated. The safety study was performed with balloon catheters carrying the maximum dose that adheres to the smooth surface of a coronary balloon without losing a large proportion of the drug before the balloon reaches the treatment site and is inflated. Treatment of up to 2 coronary arteries, each with 2 coated balloons with >7 μg sirolimus per mm 2 balloon surface, indicate inhibition of neointimal proliferation and tolerance by the animals. Histological findings identified the types of adverse effects that may be expected in case of extreme overdose. It must, however, be noticed that these are microscopic findings whereas neither the angiograms nor intracoronary flow nor left ventricular ejection fraction 4 weeks after treatment indicated compromised perfusion or other functional deficits. Furthermore, the animal model does not reflect the by far larger and hence more relevant distal embolization because of plaque debris (cholesterol, cholesterol esters, fragments of tissue, and extracellular matrix), which is unavoidable in percutaneous transluminal coronary angioplasty, transluminal peripheral angioplasty, and stent implantation. 36 The strongest inhibition of vessel narrowing was seen with the PCB. This finding compares well with previous preclinical studies investigating sirolimus-eluting stents and bare-metal stents mounted on PCBs. In these porcine studies, a significantly higher reduction of neointimal formation by paclitaxel compared with sirolimus was seen. 37, 38 These findings are in contrast to coronary clinical data indicating superiority of limus-eluting stents over paclitaxel-eluting stents 39 and PCBs in combination with bare-metal stents. 14, 15 The differences may be related to the fact that the animal model (juvenile animals, no atherosclerosis, and artificial overstretch) does not fully reflect the situation in humans. Furthermore, different biological responses may be postulated for pigs and humans.
In the present experiments, we found a similar biological effect of the crystalline sirolimus coating on the balloon and a clinically proven sirolimus-eluting stent. When first preclinical data obtained with drug-coated balloons were presented, 23 both physicians and medical device manufacturers found it hard to think that the drug released from a balloon during a short inflation could possibly be as efficacious as sustained release from permanently implanted stents. At that time, it was commonly thought that only sustained drug release would ensure persistent prevention of restenosis after angioplasty and stent implantation. 40 For coronary stents, sirolimus and its derivatives proved to be superior to paclitaxel. 39 Interestingly, in the superficial femoral artery, limus-eluting stents failed. 41 In this vascular territory, paclitaxel-coated devices are becoming the preferred treatment option. [1] [2] [3] [4] 42 More than a decade ago, the primary reason to select taxane compounds for drug-coated balloons instead of limus was the patent situation and the fact that our group had access to it. 43 Paclitaxel may be preferred because of its irreversible binding to microtubules, 21 whereas binding of limus agents to FKBP 12 is reversible. 28 Differentiated cell-specific effects may explain the persistent restenosis inhibition by paclitaxel in the case of drug-coated balloons. 44 The modes of tissue binding by limus and taxane compounds result in different transmural drug distribution with paclitaxel preferring the subintimal space and sirolimus distributing evenly through the artery. 45 Long persistence of the drug in the vessel wall has been proposed as the mechanism of action underlying the effectiveness of PCBs. 20 Drug deposits on the vessel surface driving diffusion into the arterial tissue may support intramural drug persistence in the early phase. 46 Long-term drug persistence in the vessel wall is facilitated by crystalline paclitaxel coatings. 47 For limus-coated balloons to be effective, a similar tissue kinetic may be mandatory. For stent-based delivery, crystalline sirolimus with delayed tissue retention has been successfully applied. 48 A coronary study in pigs aimed at evaluating the safety and efficacy of a zotarolimus-coated balloon in comparison with a zotarolimus-eluting stent. In both zotarolimus groups, there was a clear reduction in the neointimal area compared with the control group, which did not receive any drug on the balloon or the stent. 25 PCBs are an established treatment for coronary in-stent restenosis 5-10 with a class I level A recommendation in the European Guidelines for Revascularization. 11 However, their efficacy seems to be lower when treating drug-eluting stent restenosis compared with bare-metal stent restenosis. 49 Because the inhibition of neointimal proliferation by sirolimus-coated balloons in the porcine model was similar to the corresponding effect of sirolimus-eluting stents, a possible clinical indication for sirolimus-coated balloons could be drug-eluting stent restenosis. At the time of treatment: vessel reference diameter (RFD initial), minimal lumen diameter in-stent after implantation (MLD post), and vessel overstretch after stent implantation (overstretch). At 1-month angiography: minimal lumen diameter in-stent (MLD FU stent), late lumen loss in-stent (LLL in-stent), and diameter stenosis instent (diasten in-stent), negative values mean persistent overstretch. Histomorphometry: vessel diameter, lumen diameter, maximum neointimal thickness, vessel area, luminal area, neointimal area, injury score, inflammation score, diameter stenosis, and area stenosis. Study groups: uncoated bare-metal stents (BMS), sirolimus-eluting stents (ISAR), and bare-metal stents on Vb4 sirolimus-coated balloons (SCB+S). Values are medians with interquartile range; P value is based on the F test in a mixed model with repeated measures based on ranks. 
